title: [Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].
abstract: Patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) harboring an activating mutation of the Epidermal Growth Factor Receptor (EGFR) Gene should be treated first-line with Gefitinib, an EGFR tyrosine kinase inhibitor (TKI). EGF receptor mutations are most common in adenocarcinomas, especially non-mucinous type, rare in squamous cell carcinomas and sarcomatoid carcinomas, and do not occur in neuroendocrine carcinomas. Therefore, the Pulmonary Pathology Working Group of the Austrian Society of Pathology, after intense discussions and in consensus with Oncologists and Pulmonologists, recommends a priori EGFR mutation analysis for all cases of adenocarcinoma, and for all other NSCLC upon clinical request. This will markedly reduce waiting time for those patients, which most likely will have the greatest benefit from EGFR TKI therapy.
authors: Institut für Pathologie, MedUni Graz, Graz, Austria. helmut.popper@medunigraz.at
authors: Helmut
authors: H
authors: Popper
authors: Fritz
authors: F
authors: Wrba
authors: Ulrike
authors: U
authors: Gruber-Mösenbacher
authors: Wolfgang
authors: W
authors: Hulla
authors: Robert
authors: R
authors: Pirker
authors: Wolfgang
authors: W
authors: Hilbe
authors: Michael
authors: M
authors: Studnicka
authors: Andrea
authors: A
authors: Mohn-Staudner
authors: Ferdinand
authors: F
authors: Ploner
references: Clin Cancer Res. 2006 Jul 1;12(13):3908-14
references: 16818686
references: Cancer Sci. 2007 Jul;98(7):985-91
references: 17459062
references: Am J Surg Pathol. 2008 Jun;32(6):810-27
references: 18391747
references: Mod Pathol. 2010 Feb;23(2):159-68
references: 19855375
references: J Thorac Oncol. 2010 Oct;5(10):1706-13
references: 20871269
references: Science. 2004 Aug 20;305(5687):1163-7
references: 15284455
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: J Clin Oncol. 2005 Feb 1;23(4):857-65
references: 15681531
references: Neoplasia. 2009 Oct;11(10):1084-92
references: 19794967
references: Cancer Res. 2004 Dec 15;64(24):8919-23
references: 15604253
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: N Engl J Med. 2005 Jul 14;353(2):123-32
references: 16014882
references: Histopathology. 2009 Jan;54(1):12-27
references: 19187177
references: Anticancer Res. 2009 Jul;29(7):2767-73
references: 19596959
references: Lung Cancer. 2010 May;68(2):185-91
references: 19581016
references: J Mol Diagn. 2007 Jul;9(3):320-6
references: 17591931
references: N Engl J Med. 2009 Sep 3;361(10):958-67
references: 19692684
references: Arch Pathol Lab Med. 2009 Mar;133(3):470-7
references: 19260752
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references: 15741570